PT UBC Medical Indonesia Tbk
PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables, and Diagnostics and Equipment. The company offers next generation molecular, retina AI, infectious disease, HPV DNA test, real time PCR, TB management, and newborn screening products. PT UBC Medical Indonesia Tbk was founded in 2014 and is based in Jakarta Timur… Read more
PT UBC Medical Indonesia Tbk (LABS) - Total Liabilities
Latest total liabilities as of September 2025: Rp66.77 Billion IDR
Based on the latest financial reports, PT UBC Medical Indonesia Tbk (LABS) has total liabilities worth Rp66.77 Billion IDR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PT UBC Medical Indonesia Tbk - Total Liabilities Trend (2021–2024)
This chart illustrates how PT UBC Medical Indonesia Tbk's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PT UBC Medical Indonesia Tbk Competitors by Total Liabilities
The table below lists competitors of PT UBC Medical Indonesia Tbk ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NGX Limited
PINK:NGXLF
|
USA | $139.49K |
|
K-Tech Solutions Company Limited Class A Ordinary Shares
NASDAQ:KMRK
|
USA | $4.13 Million |
|
Teaminvest Private Group Ltd
AU:TIP
|
Australia | AU$46.12 Million |
|
Housing Development and Infrastructure Limited
NSE:HDIL
|
India | ₹62.40 Billion |
|
Kukil Metal Co. Ltd
KQ:060480
|
Korea | ₩3.51 Billion |
|
Bryton Inc.
TWO:7558
|
Taiwan | NT$42.31 Million |
|
Imexhs Ltd
AU:IME
|
Australia | AU$8.36 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down PT UBC Medical Indonesia Tbk's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PT UBC Medical Indonesia Tbk's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PT UBC Medical Indonesia Tbk (2021–2024)
The table below shows the annual total liabilities of PT UBC Medical Indonesia Tbk from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp64.84 Billion | -41.54% |
| 2023-12-31 | Rp110.93 Billion | +81.08% |
| 2022-12-31 | Rp61.26 Billion | -28.57% |
| 2021-12-31 | Rp85.76 Billion | -- |